Project Inform Perspectives 39 - December 2004

A long-awaited expanded access program for the new protease inhibitor tipranavir should make it available for 3,000–5,000 people starting in mid-to-late November. The main advantage of tipranavir is that it appears to remain active to some degree even in people whose virus has developed resistance to multiple protease inhibitors. Studies in people with multi-drug resistance have shown considerable success.

When used by itself, tipranavir is poorly retained in the body and must be boosted with 400mg daily of ritonavir. This is two to four times as much ritonavir as other protease inhibitors require. Tipranavir will be free during the expanded access program (through Boeringher-Ingelheim), as well as the requisite ritonavir boost (available from Abbott Labs’ Patient Assistance Program at 1-800-222-6885). Tipranavir is made by Boeringher-Ingelheim; ritonavir by Abbott Labs.

Details: The tipranavir program will not require people to have any particular CD4+ cell count level or viral load. To qualify, people must meet the following:

• Previously used three classes of anti-HIV drugs, such as NRTIs, NNRTIs and protease inhibitors
• Failed at least two protease inhibitor-based regimens
• Must have documented resistance to multiple protease inhibitors

While on the tipranavir regimen, people may not use any protease inhibitor other than ritonavir or any other experimental (not yet FDA approved) compound.

When the program is announced, an 800 number will be provided through which any physician can register people for the program. Call Project Inform’s Hotline for more information once the program begins.

041210
PI041203

©2004. This document is copyrighted by Project Inform, 205 13th Street, #2001, San Francisco, CA 94103. Treatment Hotline: 800-822-7422 (toll-free) or 415-558-9051 (in the San Francisco Bay Area and internationally) All Project Inform materials may be reprinted and/or distributed without prior permission. However, reprints may not be edited and must include the following text: "From Project Inform, for more information contact the Project Inform National HIV/AIDS Treatment Hotline, 800-822-7422." For permission to edit any Project Inform material for further publication, contact David Evans at the Project Inform office.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, the National Library of Medicine, Bridgestone Firestone Trust Fund, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1985, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS , or the party credited as the provider of the content.